Publications by authors named "Matthias Ritgen"

Claim this Profile
F
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Matthias Ritgen

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia von Tresckow, Matthias Ritgen

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Matthias Ritgen

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.
Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Nösslinger, Julia von Tresckow, Matthias Ritgen

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Matthias Ritgen

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
Jeff P Sharman, Talha Munir, Sebastian Grosicki, Lindsey E Roeker, John M Burke, Matthias Ritgen

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.
Michaela Kotrová, Constantin Proske, Nikos Darzentas, Anna Laqua, Britta Kehden, Matthias Ritgen

Blood· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Flow Cytometric Antibody Panel and Dedicated Analysis Algorithm for Automated Fully Standardized Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia.
Robby Engelmann, Juan Flores-Montero, Joyce Schilperoord-Vermeulen, Matthias Ritgen, Paul J Hengeveld

Am J Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Moritz Fürstenau, Sandra Robrecht, Christof Schneider, Eugen Tausch, Adam Giza, Matthias Ritgen

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Matthias Ritgen

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Matthias Ritgen

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR.
Christiane Pott, Monika Brüggemann, Matthias Ritgen, Vincent H J van der Velden, Jacques J M van Dongen

Methods Mol Biol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht, Matthias Ritgen

Blood· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The gray area of RQ-PCR-based measurable residual disease: subdividing the "positive, below quantitative range" category.
Michaela Kotrova, Eva Fronkova, Michael Svaton, Daniela Drandi, Felix Schön, Matthias Ritgen

Leukemia· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of trephine bone marrow biopsies in the era of measurable residual diseaseResults from the CLL10 trial of the German CLL Study Group (GCLLSG).
Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide, Matthias Ritgen

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Moritz Fürstenau, Arnon P Kater, Sandra Robrecht, Julia von Tresckow, Can Zhang, Matthias Ritgen

Lancet Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna-Maria Fink, Matthias Ritgen

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Matthias Ritgen

Nat Commun· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Matthias Ritgen

Blood· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Moritz Fürstenau, Yvonne J Thus, Sandra Robrecht, Clemens H M Mellink, Anne-Marie van der Kevie-Kersemaekers, Matthias Ritgen

Blood· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau, Julia von Tresckow, Matthias Ritgen

N Engl J Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Matthias Ritgen

Nat Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, Gudrun Schüler, Ursula Vehling-Kaiser, Matthias Ritgen

Leuk Lymphoma· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemia.
Anke Schilhabel, Monika Szczepanowski, Ellen J van Gastel-Mol, Janina Schillalies, Jill Ray, Matthias Ritgen

Front Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis.
Anke Schilhabel, Peter Jonas Walter, Paula Cramer, Julia von Tresckow, Saskia Kohlscheen, Matthias Ritgen

Cancers (Basel)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis